Jiang Wenbin's Form 4 filing
Cytek Biosciences, Inc. (CTKB) · filed Mar 7, 2023
- Accession no.
- 0001209191-23-016979
- Filed
- Mar 7, 2023
- Trade date
- Mar 3-7, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 2 derivative transactions. Open-market sales total $202.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jiang WenbinCIK 0001872873 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 7, 2023 | Common Stock | SSaleDisposed | −20,000 | $10.13 | −$202,600 | 7,704,439 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2023 | Common Stock | AGrant or awardAcquired | +284,900 | $0.00 | $0 | 284,900 | Direct | |
| Mar 3, 2023 | Common Stock | AGrant or awardAcquired | +188,501 | $0.00 | $0 | 188,501 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.